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OBJECTIVES: While published guidelines for managing hyper-
lipidemia are well publicized, many patients either are not
treated or managed suboptimally. This study examined physi-
cians’ knowledge, attitudes and practices in managing primary
care patients with elevated serum lipid levels. METHODS: An
online questionnaire was developed, pilot tested, and adminis-
tered to 98 primary care physicians with patients at varying risk
for coronary heart disease (CHD.) The questionnaire was admin-
istered during a two week period. Questions assessed physician’s
knowledge of current national guidelines for managing patients
with hyperlipidemia, use of various lipid lowering therapies,
lifestyle interventions to lower serum lipids, use of national
guidelines, and treatment practice for patients at varying risk for
CHD. Questions used a 5 point Likert scale (with 1 indicating
very important and 5 of little to no importance). RESULTS: The
questionnaire had an 80% response rate. Most physicians
reported following published national cholesterol guidelines all
(15%) or most (77%) of the time. Physicians perceived them-
selves to be very knowledgeable about current published national
guidelines for the management of elevated serum cholesterol
levels (53%), lifestyle interventions to lower serum lipids (50%),
and lipid lowering therapies (49%); they were considerably less
knowledgeable (19%) about costs of lipid lowering medications.
Major concerns with the use of published national guidelines
included lack of patient compliance (moderately to strongly
agree) (72%), and lack of time to adequately use guidelines
during ofﬁce visits (22%). CONCLUSIONS: Despite physician
guideline awareness, achieving desirable serum lipid levels in the
patient population remains an elusive target. Current provider
education efforts are not sufﬁcient. As more managed care orga-
nizations and group practices implement electronic medical
records, the use of evidence based treatment algorithms should
result in better management of cardiovascular risk factors,
including elevated LDL levels, in general practice populations as
well as targeted high risk groups.
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INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE
HYPERTENSION
Zhang K,Young C
Caremark, Scottsdale, AZ, USA
OBJECTIVES: The Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) recommended diuretics as ﬁrst-line
treatment for plan participants with simple hypertension in
2003. This study evaluated initial pharmaceutical treatment for
plan participants diagnosed with simple hypertension.
METHODS: The authors selected Caremark plan participants
from integrated, deidentiﬁed pharmacy and medical claims data
who were diagnosed with hypertension between Oct. 10, 2003,
and March 31, 2004. Plan participants had to be eligible for
pharmacy and medical beneﬁts one year prior and one month
post diagnosis, not have a prior diagnosis for hypertension, and
not be diagnosed with a comorbid condition during the 11-
month period studied. RESULTS: In the month following diag-
nosis, 2033 plan participants ﬁlled a prescription for at least one
antihypertensive drug. Most of these plan participants were
treated by primary-care physicians (84.9%). The remainder were
treated by either by a cardiologist (2.3%) or some other type of
specialist (12.8%). Of all those studied, 41.2% were initiated on
a diuretic either as monotherapy or in combination with one of
the other drugs. Those starting with diuretic monotherapy rep-
resented 26.3%, while 30.9% initiated therapy with a combina-
tion of antihypertensive drugs. The remaining 42.8% were
initiated on some other type of monotherapy. Of the plan par-
ticipants who initiated therapy with one antihypertensive, 31.8%
started with a diuretic, 21.7% with an ACE inhibitor, and 17.8%
with a beta-blocker. Of those prescribed a combination of drugs,
45.2% initiated on an ARB and diuretic, 34.9% on an ACE
inhibitor and diuretic. Overall, 63.69% started with generic ther-
apies and 36.31% with a brand drug. CONCLUSION: Only a
minority of plan participants diagnosed with simple hyperten-
sion, without complicating comorbid conditions, were pre-
scribed a diuretic monotherapy.
CARDIOVASCULAR DISEASE—Methods and Concepts
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PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION:AN
APPLICATION OF LATENT CLASS MODELS
Thiebaud P, Patel BV
MedImpact Healthcare Systems, Inc, San Diego, CA, USA
OBJECTIVES: To analyze patterns of antihypertensive drug uti-
lization and to forecast pharmacy utilization and costs in hyper-
tensive patients. METHODS: The sample consisted of 23,272
patients who were continuously eligible for drug beneﬁts for at
least 14 quarters. Utilization was recorded and summarized for
every quarter. The ﬁrst two quarters represented the baseline uti-
lization, and the following 12 quarters were used to determine
individual utilization trajectories. Patients were included in the
sample if they used antihypertensive drugs during the baseline
period. The sample was split into analysis and test sub-samples.
Model parameters developed in the analysis sample were used to
forecast utilization in the test sample. Utilization for the ﬁfth and
twelfth quarters was predicted based upon information gathered
from the previous quarter. The accuracy of the model was tested
by comparing predicted and actual outcomes. The analysis was
based on latent class models. Demographic characteristics, drug
beneﬁt details, and concurrent drugs served as covariates. Two
outcome variables were computed for each patient: the number
of prescriptions per quarter and the probability of exceeding a
certain cost threshold. RESULTS: For number of prescriptions,
the quarter-ahead forecasts were within 0.4 prescriptions of the
actual ﬁgures. For prescription expenditures greater than $150,
the difference between actual and estimated probabilities was
0.9% for the twelfth-quarter forecast and 4.4% for the ﬁfth-
quarter. Latent class models also accurately separated patients
into low/high cost groups and increasing/decreasing cost groups
by deﬁning cost and utilization trajectories for individual
patients. CONCLUSION: Latent class models produce accurate
forecasts that can be used to improve the management of hyper-
tensive patients. Compared to other forecasting techniques, these
models produce results that can be more easily understood by a
wide range of readers, a critical issue in outcomes research.
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VARIATION OF COST-TO-CHARGE RATIO FOR CABG
PATIENT BY HOSPITAL TYPE OVER TIME
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OBJECTIVES: Cost of care is essential for burden of illness and
cost-effectiveness studies. However, collecting cost data is very
